Phase 3 COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with severe emphysema where the damage is unevenly spread across the lungs, affecting at least 10% of the total lung tissue or 25% of the target area
- People where the difference in lung damage between the treated area and the rest of the lung on the same side is significant (at least 15 percentage points apart)
- People whose lungs show low or no air leakage between sections, as measured by specific lung imaging software or a special measurement device
- People whose total lung capacity is larger than expected for someone of their size and health (over 100% of predicted)
- People whose lungs trap an unusually high amount of air (residual volume over 175% of predicted)
- People whose breathing test results show reduced airflow, specifically FEV1 below 50% of predicted after using a bronchodilator
- People whose lungs have a reduced ability to transfer gases, specifically below 45% of predicted after using a bronchodilator
- People with a body weight in a moderate range — specifically a BMI between 18 and 35
- People who are already receiving the best available standard medical treatment for their condition
- People whose daily physical activities are limited due to their lung condition
- People who are able to take part in a pulmonary rehabilitation programme
- People whose heart pumping function is reasonably preserved (heart ejection fraction above 40%)
- People who have stopped smoking for at least 4 months
- People experiencing significant breathlessness in daily life, rated at level 2 or higher on a standard breathlessness scale
Who may not be able to join:
- People whose emphysema is spread evenly throughout the lungs rather than concentrated in specific areas
- People whose lung scans show significant air leakage between lung sections, specifically where the tissue boundary (fissure) in the target area is less than 75% intact according to specialist imaging software
- People who regularly take high-dose steroid tablets (more than 20mg of prednisone or equivalent per day)
- People with an active infection in the lungs or elsewhere in the body
- People with coronary heart disease or severely reduced heart function
- People with significant kidney or liver disease
- People with a condition that weakens the immune system
- People with a rheumatological or bone and joint condition that limits their ability to be physically active
- People who are unable to understand the study procedures due to cognitive difficulties
- People who the research team estimates may have less than one year to live (confirm with trial site)
- People who are currently smoking
- People with a cancer diagnosis where survival is estimated at less than 2 years
- People with significant psychosocial problems
- People who are pregnant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hugo G Oliveira, PhD, Hospital de Clinicas de Porto Alegre
Phone: +55 51 3359-8241
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
All-cause death; Number of participants with worsening of dyspnea; Number of participants with respiratory functional worsening; Impairment of exercise capacity; Increased oxygen use
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.